Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study - 14/03/18
the
Biobadaderm Study Group
Funding sources: The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, and Janssen). |
|
Disclosure: Dr Carretero has been reimbursed by Janssen, Abbvie, Novartis, Pfizer, MSD, and Celgene for advisory service and conference participation. Dr Ferrándiz has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Lilly, Merck Sharp & Dohme, Novartis, and Pfizer. Dr Rivera has participated in a speaker’s bureau for Abbott, Janssen, MSD, and Pfizer-Wyeth. Dr Dauden has acted as consultant for Abbott, Amgen, Astellas, Centocor Ortho Biotech Inc, Galderma, Glaxo, Jansenn-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; received honoraria form Abbott, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; participated in a speakers bureau for Abbott, Pfizer, MSD, and Janssen; and received grants from Pfizer, Abbott, Janssen, and MSD. Dr De la Cueva has acted as a consultant and speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, and Leo-Pharma. Dr Herrera-Ceballos has served as a consultant and/or speaker for and/or participated in clinical trials as principal investigator and sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. Dr Belinchón acted as a consultant for Pfizer-Wyeth, Janssen Pharmaceuticals, MSD, Almirall SA, Lilly, and Leo-Pharma and as an invited speaker for AbbVie, Pfizer-Wyeth, Janssen Pharmaceuticals, Novartis, and MSD. Dr López-Estebaranz has participated in advisory boards and received educational grants from Janssen, Abbvie, MSD, Lilly, Novartis, LeoPharma, and Pfizer. Dr Alsina has given expert testimony for Merck-Schering Plough and Abbott. Dr Carrascosa has participated as a speaker and/or advisor for Celgene, Janssen, Lilly, Novartis, Leo Pharma, Pfizer, MSD, Abbvie, Biogen, and Amgen. Dr Ferran has acted as a consultant for Abbott, Janssen, MSD, and Pfizer-Wyeth; participated in a speaker's bureau for MSD and Janssen; and received grants from Serono. Dr Baniandrés has acted as a consultant for Abbvie, Janssen, Pfizer-Wyeth, and Novartis. Dr Herrera-Acosta has served as a consultant and/or speaker with Leo Pharma, Novartis, Janssen, Lilly, Celgene, and Abbvie. Dr Muñoz-Santos has acted as a consultant for Abbott, Janssen, and Pfizer; received honoraria from Abbott, Janssen, Merck Pfizer-Wyeth; and Schering-Plough; given expert testimony for Abbott, Janssen, Wyeth, and Schering-Plough; and received grants from Janssen and Wyeth. Dr Garcia-Doval has received travel grants for congresses from MSD, Pfizer, and Schering. Drs Descalzo, Gómez-García, Sánchez-Carazo, Llamas-Velasco, Ruiz-Genao, and García-Doval have no conflicts of interest to disclosed. |
|
Reprints not available from the authors. |
Vol 78 - N° 4
P. 798-800 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?